(ADVM) Adverum Biotechnologies - Ratings and Ratios
Gene Therapy, Ocular, Wet AMD, DME, BCM
ADVM EPS (Earnings per Share)
ADVM Revenue
Description: ADVM Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage gene-therapy company focused on ocular diseases. Its lead candidate, ixoberogene soroparvovec (Ixo-vec), is a single intravitreal injection being evaluated in a Phase 2 trial for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The pipeline also includes BGTF-027, an AAV-based therapy delivering a functional OPN1LW gene to treat blue-cone monochromacy. The firm operates under multiple licensing and collaboration agreements with institutions such as the University of California, GenSight Biologics, Ray Therapeutics, Lexeo Therapeutics, and Virovek.
Key recent metrics: (1) ADVM reported a cash balance of roughly $150 million at year-end 2024, providing a runway of about 18 months under current burn rates; (2) the company closed a $150 million private placement in Q2 2024, diluting existing shareholders but funding ongoing Phase 2 trials; (3) the ocular-gene-therapy market is projected to grow at a CAGR of ~12 % through 2030, driven by unmet needs in wAMD and DME, which could expand the addressable market for Ixo-vec to > $5 billion. Sector-wide, the broader biotech environment remains volatile, with biotech indices trading at a 0.9× forward-PE multiple, indicating pricing pressure on early-stage therapeutic developers.
For a deeper, data-driven assessment of ADVM’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
ADVM Stock Overview
| Market Cap in USD | 96m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2014-07-31 |
ADVM Stock Ratings
| Growth Rating | -73.3% |
| Fundamental | 26.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -54.9% |
| Analyst Rating | 4.57 of 5 |
ADVM Dividends
Currently no dividends paidADVM Growth Ratios
| Growth Correlation 3m | 90.4% |
| Growth Correlation 12m | -62.1% |
| Growth Correlation 5y | -85.4% |
| CAGR 5y | -22.63% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.24 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.40 |
| Sharpe Ratio 12m | -1.34 |
| Alpha | -65.24 |
| Beta | 0.977 |
| Volatility | 77.78% |
| Current Volume | 94.1k |
| Average Volume 20d | 285.8k |
| Stop Loss | 3.9 (-8.2%) |
| Signal | -0.26 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-183.9m TTM) > 0 and > 6% of Revenue (6% = 60.0k TTM) |
| FCFTA -1.37 (>2.0%) and ΔFCFTA -101.6pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1704 % (prev 4360 %; Δ -2656 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.36 (>3.0%) and CFO -130.9m > Net Income -183.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (21.0m) change vs 12m ago 0.76% (target <= -2.0% for YES) |
| Gross Margin -110.8% (prev -24.19%; Δ -86.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.57% (prev 1.42%; Δ -0.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.04 (EBITDA TTM -121.2m / Interest Expense TTM 60.5m) >= 6 (WARN >= 3) |
Altman Z'' -53.50
| (A) 0.18 = (Total Current Assets 48.4m - Total Current Liabilities 31.4m) / Total Assets 96.2m |
| (B) -12.09 = Retained Earnings (Balance) -1.16b / Total Assets 96.2m |
| warn (B) unusual magnitude: -12.09 — check mapping/units |
| (C) -0.70 = EBIT TTM -123.3m / Avg Total Assets 175.0m |
| (D) -10.00 = Book Value of Equity -1.16b / Total Liabilities 116.4m |
| Total Rating: -53.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.58
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -91.65% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity -4.56 = -2.50 |
| 5. Debt/Ebitda -0.41 = -2.50 |
| 7. RoE -332.8% = -2.50 |
| 8. Rev. Trend -30.03% = -2.25 |
| 9. EPS Trend -83.36% = -4.17 |
What is the price of ADVM shares?
Over the past week, the price has changed by -5.13%, over one month by +22.83%, over three months by +59.18% and over the past year by -47.79%.
Is Adverum Biotechnologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ADVM is around 3.54 USD . This means that ADVM is currently overvalued and has a potential downside of -16.71%.
Is ADVM a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADVM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.5 | 358.8% |
| Analysts Target Price | 19.5 | 358.8% |
| ValueRay Target Price | 3.8 | -9.6% |
Last update: 2025-10-18 03:45
ADVM Fundamental Data Overview
P/S = 95.6878
P/B = 0.9297
Beta = 0.977
Revenue TTM = 1.00m USD
EBIT TTM = -123.3m USD
EBITDA TTM = -121.2m USD
Long Term Debt = 92.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.36m USD (from shortTermDebt, last quarter)
Debt = 92.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.8m USD (from netDebt column, last quarter)
Enterprise Value = 143.5m USD (95.7m + Debt 92.2m - CCE 44.4m)
Interest Coverage Ratio = -2.04 (Ebit TTM -123.3m / Interest Expense TTM 60.5m)
FCF Yield = -91.65% (FCF TTM -131.5m / Enterprise Value 143.5m)
FCF Margin = -13.2k% (FCF TTM -131.5m / Revenue TTM 1.00m)
Net Margin = -18.4k% (Net Income TTM -183.9m / Revenue TTM 1.00m)
Gross Margin = -110.8% ((Revenue TTM 1.00m - Cost of Revenue TTM 2.11m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.49 (Enterprise Value 143.5m / Total Assets 96.2m)
Interest Expense / Debt = 1.30% (Interest Expense 1.20m / Debt 92.2m)
Taxrate = -0.0% (0.0 / -130.9m)
NOPAT = -123.3m (EBIT -123.3m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 1.54 (Total Current Assets 48.4m / Total Current Liabilities 31.4m)
Debt / Equity = -4.56 (negative equity) (Debt 92.2m / totalStockholderEquity, last quarter -20.2m)
Debt / EBITDA = -0.41 (negative EBITDA) (Net Debt 49.8m / EBITDA -121.2m)
Debt / FCF = -0.38 (negative FCF - burning cash) (Net Debt 49.8m / FCF TTM -131.5m)
Total Stockholder Equity = 55.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -191.2% (out of range, set to none)
RoE = -332.8% (Net Income TTM -183.9m / Total Stockholder Equity 55.3m)
RoCE = -83.63% (EBIT -123.3m / Capital Employed (Equity 55.3m + L.T.Debt 92.2m))
RoIC = -223.2% (out of range, set to none) (NOPAT -123.3m / Invested Capital 55.3m)
WACC = 5.54% (E(95.7m)/V(187.9m) * Re(9.62%) + D(92.2m)/V(187.9m) * Rd(1.30%) * (1-Tc(-0.0)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -39.80%
Fair Price DCF = unknown (Cash Flow -131.5m)
EPS Correlation: -83.36 | EPS CAGR: -65.54% | SUE: -0.11 | # QB: 0
Revenue Correlation: -30.03 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for ADVM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle